Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 4/2016

01-08-2016 | Research Article

Patient and medication-related factors associated with hospital-acquired hyponatremia in patients hospitalized from heart failure

Authors: S. Saepudin, Patrick A. Ball, Hana Morrissey

Published in: International Journal of Clinical Pharmacy | Issue 4/2016

Login to get access

Abstract

Background Hyponatremia has been known as an important predictor of clinical outcomes in patients with heart failure (HF). While information on hyponatremia in patients with HF has been available abundantly, information on factors associated with increased risk of developing hospital-acquired hyponatremia (HAH) is still limited. Objective To identify patients and medication-related factors associated with HAH in patients hospitalized from HF. Setting Fatmawati Hospital in Jakarta, Indonesia. Methods This is a nested case–control study with patients developing HAH served as case group and each patient in case group was matched by age and gender to three patients in control group. Patients included in this study are patients hospitalized from HF, and coded with I.50 according to ICD-10, during 2011–2013 at Fatmawati Hospital in Jakarta, Indonesia. Information retrieved from patients’ medical records included demographic profiles, vital signs and symptoms at admission, past medical history, medication during hospitalization and clinical chemistry laboratory records. Multivariable logistic regression analysis was performed to find out patient and treatment-related factors associated with the development of HAH. Main outcome measures Patients and medication related factors having significant association with HAH. Results Four hundreds sixty-four patients were included in this study and 45 of them (9.7 %) met criteria of developing HAH so then, accordingly, 135 patients were selected as controls. 36 patient- and 22 treatment-related factors were analyzed in univariate logistic regression resulted in 20 factors having p value <0.2 and were included in multivariable logistic regression analysis. Final factors showing significant association with HAH are presence of ascites at admission (odds ratio = 4.7; 95 % confidence interval 1.9–11.5) and administration of amiodarone (3.2; 1.3–7.4) and heparin (3.1; 1.2–7.3) during hospital stay. Conclusion Presence of ascites at admission was found as patient-related factors associated with HAH in this study. In addition, administration of amiodarone and heparin during hospital stay were found as medication-related factors associated with HAH in patients hospitalized from HF.
Literature
1.
go back to reference Sato N, Gheorghiade M, Kajimoto K, Munakata R, Minami Y, Mizuno M, Aokage T, Asai K, Sakata Y, Yumino D, et al. Hyponatremia and in-hospital mortality in patients admitted for heart failure (from the ATTEND registry). Am J Cardiol. 2013;111(7):1019–25.CrossRefPubMed Sato N, Gheorghiade M, Kajimoto K, Munakata R, Minami Y, Mizuno M, Aokage T, Asai K, Sakata Y, Yumino D, et al. Hyponatremia and in-hospital mortality in patients admitted for heart failure (from the ATTEND registry). Am J Cardiol. 2013;111(7):1019–25.CrossRefPubMed
2.
go back to reference Saepudin S, Ball PA, Morrissey H. Hyponatremia during hospitalization and in-hospital mortality in patients hospitalized from heart failure. BMC Cardiovasc Disord. 2015;15:88.CrossRefPubMedPubMedCentral Saepudin S, Ball PA, Morrissey H. Hyponatremia during hospitalization and in-hospital mortality in patients hospitalized from heart failure. BMC Cardiovasc Disord. 2015;15:88.CrossRefPubMedPubMedCentral
3.
go back to reference Hauptman PJ. Clinical challenge of hyponatremia in heart failure. J Hosp Med. 2012;7(Suppl 4):S6–10.CrossRefPubMed Hauptman PJ. Clinical challenge of hyponatremia in heart failure. J Hosp Med. 2012;7(Suppl 4):S6–10.CrossRefPubMed
4.
go back to reference Kearney MT, Fox KAA, Lee AJ, Prescott RJ, Shah AM, Batin PD, Baig W, Lindsay S, Callahan TS, Shell WE, et al. Predicting death due to progressive heart failure in patients with mild-to-moderate chronic heart failure. J Am Coll Cardiol. 2002;40(10):1801–8.CrossRefPubMed Kearney MT, Fox KAA, Lee AJ, Prescott RJ, Shah AM, Batin PD, Baig W, Lindsay S, Callahan TS, Shell WE, et al. Predicting death due to progressive heart failure in patients with mild-to-moderate chronic heart failure. J Am Coll Cardiol. 2002;40(10):1801–8.CrossRefPubMed
6.
go back to reference Allen LA, Gheorghiade M, Reid KJ, Dunlay SM, Chan PS, Hauptman PJ, Zannad F, Konstam MA, Spertus JA. Identifying patients hospitalized with heart failure at risk for unfavorable future quality of life. Circ Cardiovasc Qual Outcomes. 2011;4(4):389–98.CrossRefPubMedPubMedCentral Allen LA, Gheorghiade M, Reid KJ, Dunlay SM, Chan PS, Hauptman PJ, Zannad F, Konstam MA, Spertus JA. Identifying patients hospitalized with heart failure at risk for unfavorable future quality of life. Circ Cardiovasc Qual Outcomes. 2011;4(4):389–98.CrossRefPubMedPubMedCentral
7.
go back to reference Hoorn EJ, Lindemans J, Zietse R. Development of severe hyponatraemia in hospitalized patients: treatment-related risk factors and inadequate management. Nephrol Dial Transplant. 2006;21(1):70–6.CrossRefPubMed Hoorn EJ, Lindemans J, Zietse R. Development of severe hyponatraemia in hospitalized patients: treatment-related risk factors and inadequate management. Nephrol Dial Transplant. 2006;21(1):70–6.CrossRefPubMed
8.
go back to reference Thompson C, Hoorn EJ. 1 Hyponatraemia: an overview of frequency, clinical presentation and complications. Best Pract Res Clin Endocrinol Metab. 2012;26:S1–6.CrossRefPubMed Thompson C, Hoorn EJ. 1 Hyponatraemia: an overview of frequency, clinical presentation and complications. Best Pract Res Clin Endocrinol Metab. 2012;26:S1–6.CrossRefPubMed
9.
go back to reference Bettari L, Fiuzat M, Shaw LK, Wojdyla DM, Metra M, Felker GM, O’Connor CM. Hyponatremia and long-term outcomes in chronic heart failure—an observational study from the Duke Databank for Cardiovascular Diseases. J Card Fail. 2012;18(1):74–81.CrossRefPubMed Bettari L, Fiuzat M, Shaw LK, Wojdyla DM, Metra M, Felker GM, O’Connor CM. Hyponatremia and long-term outcomes in chronic heart failure—an observational study from the Duke Databank for Cardiovascular Diseases. J Card Fail. 2012;18(1):74–81.CrossRefPubMed
10.
go back to reference Essebag V, Genest J, Suissa S, Pilote L. The nested case–control in cardiology. Am Heart J. 2003;146(4):581–90.CrossRefPubMed Essebag V, Genest J, Suissa S, Pilote L. The nested case–control in cardiology. Am Heart J. 2003;146(4):581–90.CrossRefPubMed
11.
go back to reference Biesheuvel CJ, Vergouwe Y, Oudega R, Hoes A, Grobbee DE, Moons KG. Advantages of the nested case–control design in diagnostic research. BMC Med Res Methodol. 2008;8(48):1–7. Biesheuvel CJ, Vergouwe Y, Oudega R, Hoes A, Grobbee DE, Moons KG. Advantages of the nested case–control design in diagnostic research. BMC Med Res Methodol. 2008;8(48):1–7.
12.
go back to reference Beukhof CM, Hoorn EJ, Lindemans J, Zietse R. Novel risk factors for hospital-acquired hyponatremia: a matched case–control study. Clin Endocrinol (Oxf). 2007;66(3):367–72.CrossRef Beukhof CM, Hoorn EJ, Lindemans J, Zietse R. Novel risk factors for hospital-acquired hyponatremia: a matched case–control study. Clin Endocrinol (Oxf). 2007;66(3):367–72.CrossRef
13.
go back to reference Wald R, Jaber BL, Price LL, Upadhyay A, Madias NE. Impact of hospital-associated hyponatremia on selected outcomes. Arch Intern Med. 2010;170(3):294–302.CrossRefPubMed Wald R, Jaber BL, Price LL, Upadhyay A, Madias NE. Impact of hospital-associated hyponatremia on selected outcomes. Arch Intern Med. 2010;170(3):294–302.CrossRefPubMed
14.
go back to reference Shchekochikhin DY, Schrier RW, Lindenfeld J, Price LL, Jaber BL, Madias NE. Outcome differences in community- versus hospital-acquired hyponatremia in patients with a diagnosis of heart failure. Circ Heart Fail. 2013;6(3):379–86.CrossRefPubMed Shchekochikhin DY, Schrier RW, Lindenfeld J, Price LL, Jaber BL, Madias NE. Outcome differences in community- versus hospital-acquired hyponatremia in patients with a diagnosis of heart failure. Circ Heart Fail. 2013;6(3):379–86.CrossRefPubMed
15.
go back to reference Yancy CW, Jessup M, Bozkurt B, Masoudi FA, Butler J, McBride PE, Casey DE Jr, McMurray JJ, Drazner MH, Mitchell JE, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147–239.CrossRefPubMed Yancy CW, Jessup M, Bozkurt B, Masoudi FA, Butler J, McBride PE, Casey DE Jr, McMurray JJ, Drazner MH, Mitchell JE, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147–239.CrossRefPubMed
16.
go back to reference Rai A, Whaley-Connell A, McFarlane S, Sowers JR. Hyponatremia, arginine vasopressin dysregulation, and vasopressin receptor antagonism. Am J Nephrol. 2006;26(6):579–89.CrossRefPubMed Rai A, Whaley-Connell A, McFarlane S, Sowers JR. Hyponatremia, arginine vasopressin dysregulation, and vasopressin receptor antagonism. Am J Nephrol. 2006;26(6):579–89.CrossRefPubMed
17.
go back to reference Ghali JK, Tam SW. The critical link of hypervolemia and hyponatremia in heart failure and the potential role of arginine vasopressin antagonists. J Card Fail. 2010;16(5):419–31.CrossRefPubMed Ghali JK, Tam SW. The critical link of hypervolemia and hyponatremia in heart failure and the potential role of arginine vasopressin antagonists. J Card Fail. 2010;16(5):419–31.CrossRefPubMed
18.
go back to reference Doggrell SA. Amiodarone-waxed and waned and waxed again. Expert Opin Pharmacother. 2001;2(11):1877–90.CrossRefPubMed Doggrell SA. Amiodarone-waxed and waned and waxed again. Expert Opin Pharmacother. 2001;2(11):1877–90.CrossRefPubMed
19.
go back to reference McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012;14(8):803–69.CrossRefPubMed McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012;14(8):803–69.CrossRefPubMed
20.
go back to reference Dutta P, Parthan G, Aggarwal A, Kumar S, Kakkar N, Bhansali A, Rotondo F, Kovacs K. Amiodarone induced hyponatremia masquerading as syndrome of inappropriate antidiuretic hormone secretion by anaplastic carcinoma of prostate. Case Rep Urol. 2014;2014:136984. doi:10.1155/2014/136984.PubMedPubMedCentral Dutta P, Parthan G, Aggarwal A, Kumar S, Kakkar N, Bhansali A, Rotondo F, Kovacs K. Amiodarone induced hyponatremia masquerading as syndrome of inappropriate antidiuretic hormone secretion by anaplastic carcinoma of prostate. Case Rep Urol. 2014;2014:136984. doi:10.​1155/​2014/​136984.PubMedPubMedCentral
21.
go back to reference Pham L, Shaer AJ, Marnejon T. Hyponatremia—a rare but serious complication of amiodarone: a case report and review of the literature. Case Rep Nephrol Urol. 2013;3(1):46–50.CrossRefPubMedPubMedCentral Pham L, Shaer AJ, Marnejon T. Hyponatremia—a rare but serious complication of amiodarone: a case report and review of the literature. Case Rep Nephrol Urol. 2013;3(1):46–50.CrossRefPubMedPubMedCentral
22.
go back to reference Ikagemi H, Shiga T, Tsushima T, Nirei T, Kasanuki H. Syndrome of inappropriate antidiuretic hormone secretion (SIADH) induced by amiodarone: a report on two cases. J Cardiovasc Pharmacol Ther. 2002;7(1):25–8.CrossRef Ikagemi H, Shiga T, Tsushima T, Nirei T, Kasanuki H. Syndrome of inappropriate antidiuretic hormone secretion (SIADH) induced by amiodarone: a report on two cases. J Cardiovasc Pharmacol Ther. 2002;7(1):25–8.CrossRef
23.
go back to reference Oster JR, Singer I, Fishman LM. Heparin-induced aldosterone suppression and hyperkalemia. Am J Med. 1995;98:575–86.CrossRefPubMed Oster JR, Singer I, Fishman LM. Heparin-induced aldosterone suppression and hyperkalemia. Am J Med. 1995;98:575–86.CrossRefPubMed
24.
go back to reference Bengalorkar GM, Sarala N, Venkatrathnamma PN, Kumar TN. Effect of heparin and low-molecular weight heparin on serum potassium and sodium levels. J Pharmacol Pharmacother. 2011;2(4):266–9.CrossRefPubMedPubMedCentral Bengalorkar GM, Sarala N, Venkatrathnamma PN, Kumar TN. Effect of heparin and low-molecular weight heparin on serum potassium and sodium levels. J Pharmacol Pharmacother. 2011;2(4):266–9.CrossRefPubMedPubMedCentral
25.
go back to reference Norman NE, Sneed AM, Brown C, Ellis CA, Minard G, Brown RO. Heparin-induced hyponatremia. Ann Pharmacother. 2004;38(3):404–7.CrossRefPubMed Norman NE, Sneed AM, Brown C, Ellis CA, Minard G, Brown RO. Heparin-induced hyponatremia. Ann Pharmacother. 2004;38(3):404–7.CrossRefPubMed
26.
go back to reference Greenberg A, Verbalis JG, Amin AN, Burst VR, Chiodo Iii JA, Chiong JR, Dasta JF, Friend KE, Hauptman PJ, Peri A, et al. Current treatment practice and outcomes. Report of the hyponatremia registry. Kidney Int. 2015;88(1):167–77.CrossRefPubMedPubMedCentral Greenberg A, Verbalis JG, Amin AN, Burst VR, Chiodo Iii JA, Chiong JR, Dasta JF, Friend KE, Hauptman PJ, Peri A, et al. Current treatment practice and outcomes. Report of the hyponatremia registry. Kidney Int. 2015;88(1):167–77.CrossRefPubMedPubMedCentral
27.
go back to reference Nemerovski C, Hutchinson DJ. Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review. Clin Ther. 2010;32(6):1015–32.CrossRefPubMed Nemerovski C, Hutchinson DJ. Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review. Clin Ther. 2010;32(6):1015–32.CrossRefPubMed
28.
go back to reference Verbalis JG, Goldsmith SR, Greenberg A, Schrier RW, Sterns RH. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med. 2007;120(11 Suppl 1):S1–21.CrossRefPubMed Verbalis JG, Goldsmith SR, Greenberg A, Schrier RW, Sterns RH. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med. 2007;120(11 Suppl 1):S1–21.CrossRefPubMed
29.
Metadata
Title
Patient and medication-related factors associated with hospital-acquired hyponatremia in patients hospitalized from heart failure
Authors
S. Saepudin
Patrick A. Ball
Hana Morrissey
Publication date
01-08-2016
Publisher
Springer International Publishing
Published in
International Journal of Clinical Pharmacy / Issue 4/2016
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-016-0296-3

Other articles of this Issue 4/2016

International Journal of Clinical Pharmacy 4/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine